

esperoct[®]

*antihemophilic factor (recombinant),
glycopegylated-exei*

SAMPLE PROGRAM

**Gain clinical experience with Esperoct[®],
an EHL flexibility factor^{1,a}**

^aPrior to reconstitution, Esperoct[®] can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

INDICATIONS AND USAGE

Esperoct[®] [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

- Esperoct[®] is not indicated for the treatment of von Willebrand disease

EHL=extended half-life.



Please see Important Safety Information throughout.

Please see Prescribing Information [here](#).



Model is for illustrative purposes only.

Esperoct®: THE FLEXIBILITY FACTOR

FOR WHEREVER THEIR DAY TAKES THEM^{1,a}

Esperoct®—an EHL flexibility factor that offers¹⁻⁶:



The **broadest temperature stability^a**
(36 °F to 104 °F)



Individualized prophylaxis dosing frequency^b



Compact packaging
for flexible storage



Bleed protection for all ages, from pediatric to adult

Novo Nordisk is pleased to provide Esperoct® samples to eligible practitioners for appropriate patients.^c

You will receive 18,000 IUs of Esperoct® in the following vial sizes as a single shipment^d:

Product #	7101958	7101954	7101955
Vial Size	500 IU	1000 IU	3000 IU
Qty.	6	6	3



^aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.¹ See Prescribing Information for complete product storage information.

^bBased on bleeding episodes. See Prescribing Information for complete dosing instructions.

^cSome restrictions apply to participation.

^dA valid state license number is required to order samples.

IMPORTANT SAFETY INFORMATION

Contraindications

- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Please see Important Safety Information throughout.

Please see Prescribing Information [here](#).

EHL=extended half-life.

esperoct®
antihemophilic factor (recombinant),
glycopegylated-exei

esperoct[®]

*antihemophilic factor (recombinant),
glycopegylated-exei*

To enroll in the Esperoct[®]
Sample Program, please contact
your Novo Nordisk representative

Scan this code using the camera on your
smartphone to find a local representative.



IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct[®] and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct[®] or if the expected plasma Factor VIII activity levels are not attained
- Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct[®] infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct[®] and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct[®]

Adverse Reactions

- The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

REFERENCES: 1. Esperoct[®] [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2. Elocatate[®] [package insert]. Bioverativ Therapeutics Inc; 2023. 3. Adynovate[®] [package insert]. Lexington, MA: Baxalta US Inc.; 2023. 4. Jivi[®] [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018. 5. Altuviiio[®] [package insert]. Bioverativ Therapeutics Inc; 2023. 6. Afstyla[®] [package insert]. Marburg, Germany: CSL Behring GmbH; 2023.



Please see Important Safety Information throughout.

Please see Prescribing Information [here](#).

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Esperoct[®] is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2024 Novo Nordisk All rights reserved. US24ESP00020 April 2024